DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
4.600
+0.060 (1.32%)
At close: Jul 22, 2025, 4:00 PM
4.600
0.00 (0.00%)
After-hours: Jul 22, 2025, 4:04 PM EDT
DiaMedica Therapeutics Employees
As of December 31, 2024, DiaMedica Therapeutics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$964,286
Market Cap
197.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
DMAC News
- 1 day ago - DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline - Business Wire
- 5 days ago - DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer - Business Wire
- 4 weeks ago - DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes - Business Wire
- 2 months ago - DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 - Business Wire
- 2 months ago - DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia - Business Wire
- 2 months ago - DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025 - Business Wire
- 2 months ago - DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights - Business Wire